159 related articles for article (PubMed ID: 33498212)
1. Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology.
Spronck EA; Vallès A; Lampen MH; Montenegro-Miranda PS; Keskin S; Heijink L; Evers MM; Petry H; Deventer SJV; Konstantinova P; Haan M
Brain Sci; 2021 Jan; 11(2):. PubMed ID: 33498212
[TBL] [Abstract][Full Text] [Related]
2. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
3. AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models.
Spronck EA; Brouwers CC; Vallès A; de Haan M; Petry H; van Deventer SJ; Konstantinova P; Evers MM
Mol Ther Methods Clin Dev; 2019 Jun; 13():334-343. PubMed ID: 30984798
[TBL] [Abstract][Full Text] [Related]
4. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
[TBL] [Abstract][Full Text] [Related]
5. AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes.
Keskin S; Brouwers CC; Sogorb-Gonzalez M; Martier R; Depla JA; Vallès A; van Deventer SJ; Konstantinova P; Evers MM
Mol Ther Methods Clin Dev; 2019 Dec; 15():275-284. PubMed ID: 31737741
[TBL] [Abstract][Full Text] [Related]
6. Functional Intercellular Transmission of miHTT via Extracellular Vesicles: An In Vitro Proof-of-Mechanism Study.
Morais RDVS; Sogorb-González M; Bar C; Timmer NC; Van der Bent ML; Wartel M; Vallès A
Cells; 2022 Sep; 11(17):. PubMed ID: 36078156
[TBL] [Abstract][Full Text] [Related]
7. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
8. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
[TBL] [Abstract][Full Text] [Related]
9. Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy.
Vallès A; Evers MM; Stam A; Sogorb-Gonzalez M; Brouwers C; Vendrell-Tornero C; Acar-Broekmans S; Paerels L; Klima J; Bohuslavova B; Pintauro R; Fodale V; Bresciani A; Liscak R; Urgosik D; Starek Z; Crha M; Blits B; Petry H; Ellederova Z; Motlik J; van Deventer S; Konstantinova P
Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827977
[TBL] [Abstract][Full Text] [Related]
10. AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins.
Evers MM; Konstantinova P
Expert Opin Biol Ther; 2020 Oct; 20(10):1121-1124. PubMed ID: 32658606
[No Abstract] [Full Text] [Related]
11. Targeted Delivery and Tolerability of MRI-Guided CED Infusion into the Cerebellum of Nonhuman Primates.
Salegio EA; Campagna MV; Allen PC; Stockinger DE; Song Y; Hwa GGC
Hum Gene Ther Methods; 2018 Aug; 29(4):169-176. PubMed ID: 29953257
[TBL] [Abstract][Full Text] [Related]
12. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.
Miniarikova J; Zanella I; Huseinovic A; van der Zon T; Hanemaaijer E; Martier R; Koornneef A; Southwell AL; Hayden MR; van Deventer SJ; Petry H; Konstantinova P
Mol Ther Nucleic Acids; 2016 Mar; 5(3):e297. PubMed ID: 27003755
[TBL] [Abstract][Full Text] [Related]
13. PhP.B Enhanced Adeno-Associated Virus Mediated-Expression Following Systemic Delivery or Direct Brain Administration.
Pietersz KL; Plessis FD; Pouw SM; Liefhebber JM; van Deventer SJ; Martens GJM; Konstantinova PS; Blits B
Front Bioeng Biotechnol; 2021; 9():679483. PubMed ID: 34414171
[TBL] [Abstract][Full Text] [Related]
14. Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5
Majowicz A; Salas D; Zabaleta N; Rodríguez-Garcia E; González-Aseguinolaza G; Petry H; Ferreira V
Mol Ther; 2017 Aug; 25(8):1831-1842. PubMed ID: 28596114
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
[TBL] [Abstract][Full Text] [Related]
16. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
17. Transduction profiles in minipig following MRI guided delivery of AAV-5 into thalamic and corona radiata areas.
Pietersz KL; Pouw S; Klima J; Ellederova Z; Bohuslavova B; Chrastina J; Liscak R; Urgosik D; Starek Z; Crha M; Lewis O; Wooley M; Johnson D; Brouwers CC; Evers M; Motlik J; Martens GJM; Konstantinova PS; Blits B
J Neurosci Methods; 2022 Jan; 365():109382. PubMed ID: 34637809
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
[TBL] [Abstract][Full Text] [Related]
19. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.
Stiles DK; Zhang Z; Ge P; Nelson B; Grondin R; Ai Y; Hardy P; Nelson PT; Guzaev AP; Butt MT; Charisse K; Kosovrasti V; Tchangov L; Meys M; Maier M; Nechev L; Manoharan M; Kaemmerer WF; Gwost D; Stewart GR; Gash DM; Sah DW
Exp Neurol; 2012 Jan; 233(1):463-71. PubMed ID: 22119622
[TBL] [Abstract][Full Text] [Related]
20. Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors.
Glushakova LG; Timmers AM; Pang J; Teusner JT; Hauswirth WW
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3505-13. PubMed ID: 16877422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
